Jaguar Health, Inc.

JAGX

US47010C8626

Pharmaceuticals

Delayed Nasdaq Other stock markets 08:08:13 12/06/2026 pm IST			5-day change	1st Jan Change
2.650 ^USD	-5.86%		-3.57%	-91.72%

09/06	Jaguar Health, Inc. announced that it expects to receive $41.99992 million in funding	CI
26/05	Jaguar Health, Inc., Q1 2026 Earnings Call, May 26, 2026

Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

Published on 04/07/2026 at 05:35 pm IST

S&P Capital IQ

JAGUAR HEALTH, INC.

-5.86%

Jaguar Health, Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported revenue was USD 11.51 million compared to USD 11.69 million a year ago. Net loss was USD 53.43 million compared to USD 38.49 million a year ago.

Basic loss per share from continuing operations was USD 803.9508.

Latest news about Jaguar Health, Inc.

09/06	Jaguar Health, Inc. announced that it expects to receive $41.99992 million in funding	CI
26/05	Jaguar Health, Inc., Q1 2026 Earnings Call, May 26, 2026
21/05	Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
10/04	Jaguar Health, Inc., Q4 2025 Earnings Call, Apr 10, 2026
07/04	Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
07/04	Jaguar Health, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/02	Jaguar Health to Pay Special Stock Dividend	MT
16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI
24/11	Jaguar Health, Inc. announced that it has received $10.81 million in funding	CI
21/11	Jaguar Health's Napo Pharmaceuticals Submits Amended Crofelemer Trial Protocol to FDA	MT
17/11	Jaguar Health, Inc., Q3 2025 Earnings Call, Nov 17, 2025
17/11	Gastrointestinal drugmaker Jaguar Health's Q3 net loss narrows	RE
15/11	Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	Jaguar Health, Inc. announced that it expects to receive $10.81 million in funding	CI

Chart Jaguar Health, Inc.

Duration

Period

JAGX: Dynamic Chart

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Employees

Sector

Pharmaceuticals

More about the company